{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:24:34Z","timestamp":1791883474277,"version":"4.3.4"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>As the primary facilities authorized to dispense methadone, opioid treatment programs (OTPs) are a critical access point for medications for opioid use disorder (MOUD). However, research is limited on the extent to which OTPs offer a broad range of MOUD and on the characteristics of programs that provide more comprehensive medication offerings.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the percentage of US OTPs offering all 3 forms of MOUD (methadone, buprenorphine, and naltrexone) and compare organizational and county characteristics of OTPs with different MOUD service offerings.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This longitudinal cross-sectional study used data on a panel of OTPs listed in the annual National Directory of Drug and Alcohol Use Treatment Facilities from 2017 to 2023.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Measures included the percentage of OTPs offering buprenorphine, extended-release naltrexone, or all 3 MOUD from 2017 to 2023 (assuming all OTPs offered methadone). Descriptive statistics on organizational and county characteristics of OTPs by MOUD offerings were collected. Three longitudinal logistic regression models were used to estimate the odds of different MOUD offerings within OTPs, adjusting for organizational and county-level characteristics.<\/jats:p><\/jats:sec>Results<\/jats:title>This analysis included 10\u202f298 facility-year observations, ranging from 1211 in 2017 to 1421 in 2023. From 2017 to 2023, the percentage of OTPs offering MOUD beyond methadone increased (buprenorphine: 811 [67.0%] in 2017 to 1209 [85.1%] in 2023; naltrexone: 463 [38.2%] in 2017 to 749 [52.7%] in 2023; all 3 MOUD: 402 [33.2%] in 2017 to 639 [45.0%] in 2023). OTPs offering all 3 MOUD (3985 [38.7%]) had significantly higher odds of accepting Medicare (adjusted odds ratio [AOR], 2.14; 95% CI, 1.67-2.74); offering peer services (AOR, 1.63; 95% CI, 1.25-2.12), mental health services (AOR, 2.07; 95% CI, 1.53-2.80), and telemedicine services (AOR, 1.53; 95% CI, 1.22-1.92); and being private nonprofit (AOR, 7.45; 95% CI, 4.67-11.87) or government operated (AOR, 41.83; 95% CI, 19.71-88.75) compared with private for profit.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In this cross-sectional study of OTPs, although the availability of MOUD beyond methadone increased over time, most OTPs still did not offer all 3 forms of MOUD as of 2023. Specific organizational characteristics, such as being government operated and accepting Medicare, were associated with more comprehensive MOUD offerings. Future research should evaluate why OTPs vary in their MOUD offerings.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.17616","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T15:31:06Z","timestamp":1750951866000},"page":"e2517616","source":"Crossref","is-referenced-by-count":6,"title":["Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs"],"prefix":"10.1001","volume":"8","author":[{"given":"Zoe","family":"Lindenfeld","sequence":"first","affiliation":[{"name":"Edward J. Bloustein School of Planning and Public Policy, Rutgers University, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Cantor","sequence":"additional","affiliation":[{"name":"RAND, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda I.","family":"Mauri","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, School of Public Health, University of Maryland, College Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachini","family":"Bandara","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarya","family":"Suryavanshi","sequence":"additional","affiliation":[{"name":"RAND, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Population Health, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"8","key":"zoi250555r4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s11606-017-4077-z","article-title":"Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity.","volume":"32","author":"Wakeman","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"3","key":"zoi250555r5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi250555r6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid.","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"zoi250555r7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2016.05.002","article-title":"Impact of medication-assisted treatment for opioid addiction on Medicaid expenditures and health services utilization rates in Vermont.","volume":"67","author":"Mohlman","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"zoi250555r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1907","article-title":"Medicare payment for opioid treatment programs.","volume":"5","author":"Nakamoto","year":"2024","journal-title":"JAMA Health Forum"},{"key":"zoi250555r11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jsat.2020.01.009","article-title":"Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.","volume":"111","author":"Saunders","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"zoi250555r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: qualitative study of people who use or have used heroin.","volume":"189","author":"Neale","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"zoi250555r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi250555r16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1001\/jama.2024.11913","article-title":"Treatment approaches for opioid use disorder offered in US substance use treatment facilities.","volume":"332","author":"Park","year":"2024","journal-title":"JAMA"},{"key":"zoi250555r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107616","article-title":"Characteristics and current clinical practices of opioid treatment programs in the United States.","volume":"205","author":"Jones","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi250555r18","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxae076","article-title":"Access to treatment before and after Medicare coverage of opioid treatment programs.","volume":"2","author":"Liu","year":"2024","journal-title":"Health Aff Sch"},{"key":"zoi250555r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209247","article-title":"Introduction of Medicare coverage in opioid treatment programs: findings from the first three years.","volume":"158","author":"Abraham","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"7","key":"zoi250555r21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1377\/hlthaff.2023.00148","article-title":"Changes in county-level access to medications for opioid use disorder after Medicare coverage of methadone treatment began.","volume":"42","author":"Harris","year":"2023","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"zoi250555r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.3099","article-title":"Medicare beneficiary receipt of methadone by drive time to opioid treatment programs.","volume":"8","author":"Cantor","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi250555r23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis.","volume":"24","author":"Amiri","year":"2021","journal-title":"Value Health"},{"key":"zoi250555r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108719","article-title":"Racial\/ethnic disparities in the availability of hospital based opioid use disorder treatment.","volume":"138","author":"Chang","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"zoi250555r25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.","volume":"40","author":"Hansen","year":"2013","journal-title":"J Behav Health Serv Res"},{"issue":"11","key":"zoi250555r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41128","article-title":"Patterns in geographic distribution of substance use disorder treatment facilities in the US and accepted forms of payment from 2010 to 2021.","volume":"5","author":"Cantor","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi250555r31","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review.","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"1","key":"zoi250555r32","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/08897077.2021.1975872","article-title":"Health professionals\u2019 attitudes toward medications for opioid use disorder.","volume":"43","author":"Brown","year":"2022","journal-title":"Subst Abus"},{"issue":"22","key":"zoi250555r33","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2013tackling the opioid-overdose epidemic.","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250555r34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse.","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann Intern Med"},{"key":"zoi250555r35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jsat.2015.10.003","article-title":"Extended-release naltrexone: a qualitative analysis of barriers to routine use.","volume":"62","author":"Alanis-Hirsch","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"zoi250555r36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20843","article-title":"Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States.","volume":"3","author":"Huhn","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi250555r37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties.","volume":"93","author":"Jones","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"zoi250555r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108131","article-title":"Geographic proximity to buprenorphine treatment providers in the US.","volume":"213","author":"Langabeer","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"zoi250555r39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1176\/appi.ps.201500501","article-title":"Integrating buprenorphine into an opioid treatment program: tailoring care for patients with opioid use disorders.","volume":"68","author":"Polydorou","year":"2017","journal-title":"Psychiatr Serv"},{"key":"zoi250555r14","author":"Olsen","year":"2021"},{"key":"zoi250555r1","unstructured":"US overdose deaths decrease in 2023, first time since 2018. Centers for Disease Control and Prevention. May 14, 2024. Accessed February 6, 2025. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm"},{"key":"zoi250555r2","unstructured":"Volkow? N. Investing in prevention makes good financial sense. National Institute on Drug Abuse. April 28, 2022. Accessed February 25, 2024. https:\/\/nida.nih.gov\/about-nida\/noras-blog\/2022\/04\/investing-in-prevention-makes-good-financial-sense"},{"key":"zoi250555r3","doi-asserted-by":"crossref","unstructured":"Mattick? RP, Breen? C, Kimber? J, Davoli? M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004:(3):CD002207. doi:10.1002\/14651858.CD002207.pub2","DOI":"10.1002\/14651858.CD002207.pub2"},{"key":"zoi250555r8","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health. HHS Publication No. PEP24-07-021, NSDUH Series H-59. 2024. Accessed April 9, 2025. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47095\/National%20Report\/National%20Report\/2023-nsduh-annual-national.pdf"},{"key":"zoi250555r10","unstructured":"Stoller? KB, Stephens? MC, Schorr? A. Integrated service delivery models for opioid treatment programs in an era of increasing opioid addiction, health reform, and parity. American Association for the Treatment of Opioid Dependence. July 13, 2016. Accessed February 6, 2025. https:\/\/atforum.com\/wp-content\/uploads\/2nd-Whitepaper-.pdf"},{"key":"zoi250555r15","unstructured":"Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. 2024. Accessed April 9, 2025. https:\/\/library.samhsa.gov\/sites\/default\/files\/federal-guidelines-opioid-treatment-pep24-02-011.pdf"},{"key":"zoi250555r19","doi-asserted-by":"crossref","unstructured":"Agniel? D, Cantor? JH, Maclean? JC, Simon? KI, Taylor? E. Insurance coverage and provision of opioid treatment: evidence from Medicare. National Bureau of Economic Research working paper 31884. November 2023. Accessed April 9, 2025. https:\/\/www.nber.org\/system\/files\/working_papers\/w31884\/w31884.pdf","DOI":"10.3386\/w31884"},{"key":"zoi250555r27","unstructured":"US Census Bureau. American Community Survey (ACS). Accessed January 8, 2025. https:\/\/www.census.gov\/programs-surveys\/acs"},{"key":"zoi250555r28","unstructured":"County Health Rankings & Roadmaps. 2025 annual data release. Accessed April 8, 2025. https:\/\/www.countyhealthrankings.org\/"},{"key":"zoi250555r29","unstructured":"CMS issues guidance about expanded Medicaid coverage for treatment of opioid use disorders. Centers for Medicare & Medicaid Services. December 30, 2020. Accessed February 6, 2025. https:\/\/www.cms.gov\/newsroom\/news-alert\/cms-issues-guidance-about-expanded-medicaid-coverage-treatment-opioid-use-disorders"},{"key":"zoi250555r30","unstructured":"Clemens-Cope? L, Epstein? M, Lynch? V, Winiski? E. Rapid growth in Medicaid spending and prescriptions to treat opioid use disorder and opioid overdose from 2010 to 2017. Urban Institute. July 2020. Accessed April 9, 2025. https:\/\/www.urban.org\/sites\/default\/files\/publication\/102604\/rapid-growth-in-medicaid-prescriptions-and-spending-to-treat-opioid-use-disorder-and-opioid-overdose-from-2010-to-2018.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835695\/lindenfeld_2025_oi_250555_1750269380.14284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T15:31:09Z","timestamp":1750951869000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17616","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}